C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91%
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Intrinsic Value

Cellivery Therapeutics Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 694.23 KRW. Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 75%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
1 694.23 KRW
Overvaluation 75%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Cellivery Therapeutics Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Cellivery Therapeutics Inc
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for Cellivery Therapeutics Inc cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about Cellivery Therapeutics Inc?
Bearish
Neutral
Bullish

Fundamental Analysis

6 680 KRW
-29.91%
-29.91%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Cellivery Therapeutics Inc
KR
Life Sciences Tools & Services
Market Cap
248.4B KRW
IPO
Nov 9, 2018
Employees
87
Korea
Market Cap
248.4B KRW
Industry
Life Sciences Tools & Services
IPO
Nov 9, 2018
Company Overview
Loading...
Economic Moat
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Cellivery Therapeutics Inc

Provide an overview of the primary business activities
of Cellivery Therapeutics Inc.

What unique competitive advantages
does Cellivery Therapeutics Inc hold over its rivals?

What risks and challenges
does Cellivery Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cellivery Therapeutics Inc.

Provide P/S
for Cellivery Therapeutics Inc.

Provide P/E
for Cellivery Therapeutics Inc.

Provide P/OCF
for Cellivery Therapeutics Inc.

Provide P/FCFE
for Cellivery Therapeutics Inc.

Provide P/B
for Cellivery Therapeutics Inc.

Provide EV/S
for Cellivery Therapeutics Inc.

Provide EV/GP
for Cellivery Therapeutics Inc.

Provide EV/EBITDA
for Cellivery Therapeutics Inc.

Provide EV/EBIT
for Cellivery Therapeutics Inc.

Provide EV/OCF
for Cellivery Therapeutics Inc.

Provide EV/FCFF
for Cellivery Therapeutics Inc.

Provide EV/IC
for Cellivery Therapeutics Inc.

Compare the intrinsic valuations
of Cellivery Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cellivery Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cellivery Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cellivery Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cellivery Therapeutics Inc with its peers.

Analyze the financial leverage
of Cellivery Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cellivery Therapeutics Inc.

Provide ROE
for Cellivery Therapeutics Inc.

Provide ROA
for Cellivery Therapeutics Inc.

Provide ROIC
for Cellivery Therapeutics Inc.

Provide ROCE
for Cellivery Therapeutics Inc.

Provide Gross Margin
for Cellivery Therapeutics Inc.

Provide Operating Margin
for Cellivery Therapeutics Inc.

Provide Net Margin
for Cellivery Therapeutics Inc.

Provide FCF Margin
for Cellivery Therapeutics Inc.

Show all solvency ratios
for Cellivery Therapeutics Inc.

Provide D/E Ratio
for Cellivery Therapeutics Inc.

Provide D/A Ratio
for Cellivery Therapeutics Inc.

Provide Interest Coverage Ratio
for Cellivery Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cellivery Therapeutics Inc.

Provide Quick Ratio
for Cellivery Therapeutics Inc.

Provide Current Ratio
for Cellivery Therapeutics Inc.

Provide Cash Ratio
for Cellivery Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cellivery Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cellivery Therapeutics Inc?

What is the current Free Cash Flow
of Cellivery Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cellivery Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cellivery Therapeutics Inc

Current Assets 2.9B
Cash & Short-Term Investments 133.8m
Receivables 1.7B
Other Current Assets 1.1B
Non-Current Assets 17.9B
Long-Term Investments 1B
PP&E 16B
Intangibles 365.5m
Other Non-Current Assets 439.4m
Current Liabilities 42.9B
Accounts Payable 301.3m
Accrued Liabilities 7.2B
Short-Term Debt 16.3B
Other Current Liabilities 19.2B
Non-Current Liabilities -1.9B
Long-Term Debt 2.1m
Other Non-Current Liabilities -1.9B
Efficiency

Earnings Waterfall
Cellivery Therapeutics Inc

Revenue
24.5B KRW
Cost of Revenue
-24B KRW
Gross Profit
563.7m KRW
Operating Expenses
-15.5B KRW
Operating Income
-14.9B KRW
Other Expenses
8.8B KRW
Net Income
-6.1B KRW

Free Cash Flow Analysis
Cellivery Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
32/100
Profitability
Score

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
18/100
Solvency
Score

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cellivery Therapeutics Inc

There are no price targets for Cellivery Therapeutics Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Cellivery Therapeutics Inc?

Click here to dive deeper.

Dividends

Cellivery Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Cellivery Therapeutics Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one Cellivery Therapeutics Inc stock?

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 694.23 KRW.

Is Cellivery Therapeutics Inc stock undervalued or overvalued?

Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 75%.

Back to Top